03:42 PM EST - Immunovaccine Inc. : announced today that new positive clinical data on the Company's lead cancer vaccine candidate, DPX-Survivac, will be presented as a poster at the 2014 ASCO Annual Meeting in Chicago, IL from May 30 to June 3. Results presented from the Phase I/Ib clinical study demonstrate promising early evidence of clinical activity for DPX-Survivac in ovarian cancer patients, including one patient who experienced a partial response. Immunovaccine Inc.
shares V.IMV are trading up $0.14 at $0.84.
